ADEQUACY OF HEMODIALYSIS

被引:129
作者
HAKIM, RM
DEPNER, TA
PARKER, TF
机构
[1] DALLAS NEPHROL ASSOCIATES, DALLAS, TX USA
[2] UNIV CALIF DAVIS, SACRAMENTO MED CTR, DIV NEPHROL, SACRAMENTO, CA 95817 USA
[3] UNIV TEXAS, HLTH SCI CTR, SW MED SCH, DALLAS, TX 75235 USA
关键词
ADEQUACY; HEMODIALYSIS; TAC(UREA); KT/V; BIOCOMPATIBILITY;
D O I
10.1016/S0272-6386(12)80538-5
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Despite technical advances in the delivery of hemodialysis over the past decade, the mortality rate of hemodialysisdependent, end-stage renal disease (ESRD) patients in the United States remains high. The increase in the number and severity of comorbid conditions of patients entering ESRD is a factor contributing to this high mortality. Nevertheless, there is increasing evidence that the dose of dialysis received by US patients is inadequate and that this plays a major role in the observed high mortality. In this review, we examine some of the parameters used to judge the adequacy of dialysis, as well as factors that can result in differences between prescribed and delivered dose of hemodialysis. Based on available evidence, we propose that for most patients the optimum dose of dialysis, above which further improvement of morbidity and mortality is doubtful, is represented by a delivered dose of dialysis equivalent to a Kt/V of 1.4 or greater, using biocompatible membranes. The prescription of this optimal dose of dialysis must be coupled with an ongoing effort to monitor delivery of the appropriate dose. © 1992, National Kidney Foundation. All rights reserved. All rights reserved.
引用
收藏
页码:107 / 123
页数:17
相关论文
共 79 条